Center for Translational Research on Autoimmune and Allergic Disease-CAAD, Università del Piemonte Orientale, 28100 Novara, Italy.
Immunology and General Pathology Laboratory, Department of Biotechnology and Life Sciences, University of Insubria, 21100 Varese, Italy.
Int J Mol Sci. 2024 Jan 31;25(3):1732. doi: 10.3390/ijms25031732.
Bladder cancer (BC) constitutes one of the most diagnosed types of cancer worldwide. Advancements in and new methodologies for DNA sequencing, leading to high-throughput microbiota testing, have pinpointed discrepancies in urinary microbial fingerprints between healthy individuals and patients with BC. Although several studies suggest an involvement of microbiota dysbiosis in the pathogenesis, progression, and therapeutic response to bladder cancer, an established direct causal relationship remains to be elucidated due to the lack of standardized methodologies associated with such studies. This review compiles an overview of the microbiota of the human urinary tract in healthy and diseased individuals and discusses the evidence to date on microbiome involvement and potential mechanisms by which the microbiota may contribute to the development of BC. We also explore the potential profiling of urinary microbiota as a biomarker for risk stratification, as well as the prediction of the response to intravesical therapies and immunotherapy in BC patients. Further investigation into the urinary microbiome of BC patients is imperative to unravel the complexities of the role played by host-microbe interactions in shaping wellness or disease and yield valuable insights into and strategies for the prevention and personalized treatment of BC.
膀胱癌(BC)是全球最常见的癌症类型之一。DNA 测序技术的进步和新方法的出现,推动了高通量微生物组检测,从而确定了健康个体和 BC 患者之间尿液微生物指纹图谱的差异。尽管有几项研究表明,微生物失调与膀胱癌的发病机制、进展和治疗反应有关,但由于缺乏与这些研究相关的标准化方法,因此尚未阐明明确的直接因果关系。这篇综述总结了健康和患病个体的人类尿路微生物组概述,并讨论了迄今为止关于微生物组参与以及微生物组可能有助于 BC 发展的潜在机制的证据。我们还探讨了将尿液微生物组作为风险分层生物标志物的潜力,以及预测 BC 患者对膀胱内治疗和免疫治疗的反应的潜力。进一步研究 BC 患者的尿液微生物组对于揭示宿主-微生物相互作用在塑造健康或疾病中的复杂作用至关重要,并为 BC 的预防和个性化治疗提供有价值的见解和策略。